Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Advanced Proteome Therapeutics Corporation (APTCF)

Compare
0.0002
0.0000
(0.00%)
At close: April 11 at 4:00:00 PM EDT
Loading Chart for APTCF
  • Previous Close 0.0000
  • Open 0.0002
  • Bid --
  • Ask --
  • Day's Range 0.0002 - 0.0002
  • 52 Week Range 0.0002 - 0.0002
  • Volume 14,313
  • Avg. Volume 0
  • Market Cap (intraday) 149,630
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.

www.advancedproteome.com

--

Full Time Employees

July 31

Fiscal Year Ends

Recent News: APTCF

View More

Performance Overview: APTCF

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

APTCF
0.00%
S&P/TSX Composite index (^GSPTSE)
4.19%

1-Year Return

APTCF
0.00%
S&P/TSX Composite index (^GSPTSE)
6.68%

3-Year Return

APTCF
98.18%
S&P/TSX Composite index (^GSPTSE)
8.25%

5-Year Return

APTCF
99.50%
S&P/TSX Composite index (^GSPTSE)
66.50%

Compare To: APTCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: APTCF

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -126.04%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -2.04M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.7k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.41M

Research Analysis: APTCF

View More

Company Insights: APTCF

Research Reports: APTCF

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.